Consistent expression of PD-L1 in tumor microenvironment with peripheral PD-1/PD-L1 in circulating T lymphocytes of operable breast cancer: a diagnostic test

Table 2 The relationship between PD-L1 expression in TME and clinicopathological characters

	PD-L1 expression		P
	Positive (n = 24)	Negative (n = 49)	P
Age, n(%)^a
≤ 50	8(33.33%)	18(36.73%)
> 50	16(66.67%)	31(63.27%)	0.776
Tumor size, n(%)^b
T1	14(58.33%)	28(57.14%)
T2	9(37.50%)	19(38.78%)
T3	1(4.17%)	2(4.08%)	0.930
Lymph node metastasis, n(%)^a
Yes	7(29.17%)	13(26.53%)
No	17(70.83%)	36(73.47%)	0.812
cTNM stage, n(%)^b
I	13(54.17%)	24(48.98%)
II	6(25.00%)	15(30.61%)
III	5(20.83%)	10(20.41%)	0.720
Histological grade, n(%)^b
I	1(5.00%)	4(10.26%)
II	14(70.00%)	31(79.49%)
III	5(25.00%)	4(10.26%)	0.131
ER, n(%)^a
Positive	16(66.67%)	38(77.55%)
Negative	8(33.33%)	11(22.45%)	0.319
PR, n(%)^a
Positive	15(62.50%)	33(67.35%)
Negative	9(37.50%)	16(32.65%)	0.682
HER-2, n(%)^a
Positive	7(29.17%)	8(16.67%)
Negative	17(70.83%)	40(83.33%)	0.218
Ki-67 index, n(%)^a
Low(≤ 14%)	6(25.00%)	15(31.25%)
High (> 14%)	18(75.00%)	33(68.75%)	0.582
Molecular subtype, n(%)c
Luminal A	5(20.83%)	13(26.53%)
Luminal B	11(45.83%)	25(51.02%)
TRIPLE-NEGATIVE BREAST CANCER	4(16.67%)	7(14.29%)
HER-2 overexpression	4(16.67%)	4(8.16%)	0.317

ISSN: 1746-1596